NO20065090L - Regiospesifikk syntese av rapamycin 42-esterderivater - Google Patents

Regiospesifikk syntese av rapamycin 42-esterderivater

Info

Publication number
NO20065090L
NO20065090L NO20065090A NO20065090A NO20065090L NO 20065090 L NO20065090 L NO 20065090L NO 20065090 A NO20065090 A NO 20065090A NO 20065090 A NO20065090 A NO 20065090A NO 20065090 L NO20065090 L NO 20065090L
Authority
NO
Norway
Prior art keywords
rapamycin
region
specific synthesis
ester derivatives
ester
Prior art date
Application number
NO20065090A
Other languages
English (en)
Norwegian (no)
Inventor
Ping Cai
Jianxin Gu
Markus Edward Ruppen
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34965235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20065090(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20065090L publication Critical patent/NO20065090L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
NO20065090A 2004-04-14 2006-11-03 Regiospesifikk syntese av rapamycin 42-esterderivater NO20065090L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56192604P 2004-04-14 2004-04-14
PCT/US2005/012266 WO2005105811A1 (en) 2004-04-14 2005-04-12 Regiospecific synthesis of rapamycin 42-ester derivatives

Publications (1)

Publication Number Publication Date
NO20065090L true NO20065090L (no) 2006-11-13

Family

ID=34965235

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065090A NO20065090L (no) 2004-04-14 2006-11-03 Regiospesifikk syntese av rapamycin 42-esterderivater

Country Status (23)

Country Link
US (1) US7268144B2 (ja)
EP (1) EP1737869A1 (ja)
JP (1) JP4224115B2 (ja)
KR (1) KR20070015544A (ja)
CN (1) CN1942476A (ja)
AR (1) AR049019A1 (ja)
AU (1) AU2005238431A1 (ja)
BR (1) BRPI0509852A (ja)
CA (1) CA2562952A1 (ja)
CL (1) CL2008000507A1 (ja)
CR (1) CR8646A (ja)
EC (1) ECSP066927A (ja)
GT (1) GT200500085A (ja)
IL (1) IL178315A0 (ja)
MX (1) MXPA06011881A (ja)
NO (1) NO20065090L (ja)
PA (1) PA8629901A1 (ja)
PE (1) PE20060253A1 (ja)
RU (1) RU2387657C2 (ja)
SG (1) SG152234A1 (ja)
TW (1) TW200536542A (ja)
UA (1) UA87492C2 (ja)
WO (1) WO2005105811A1 (ja)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2344821C2 (ru) 2002-07-30 2009-01-27 Уайт Парентеральные композиции, содержащие гидроксиэфиры рапамицина
EP1735321B1 (en) * 2004-04-14 2008-10-08 Wyeth Process for preparing rapamycin 42-esters and fk-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies
CA2562164A1 (en) * 2004-04-27 2005-11-10 Wyeth Labeling of rapamycin using rapamycin-specific methylases
TW200616633A (en) * 2004-08-10 2006-06-01 Wyeth Corp CCI-779 derivatives and methods of making same
CA2595766A1 (en) 2005-02-09 2006-08-17 Wyeth Cci-779 polymorph and use thereof
WO2007056175A2 (en) * 2005-11-04 2007-05-18 Wyeth 41-methoxy isotope labeled rapamycin 42-ester
BRPI0619493A2 (pt) * 2005-12-07 2016-09-06 Wyeth Corp forma cristalina purificada de cci-779, processo para a purificação de cc-779, produto, método para monitorar a cristalização de cci-779, kit, composição farmacêutica, método para o tratamento de câncer, e, uso de um cci-779 purificado
CN101321770A (zh) * 2005-12-07 2008-12-10 惠氏公司 由雷帕霉素42-酯硼酸酯制备雷帕霉素42-酯的可放大方法
US20070128731A1 (en) * 2005-12-07 2007-06-07 Wyeth Methods for preparing crystalline rapamycin and for measuring crystallinity of rapamycin compounds using differential scanning calorimetry
KR20080106225A (ko) * 2006-03-07 2008-12-04 와이어쓰 마크롤라이드 면역억제제의 수용성 폴리에틸렌 글리콜 콘쥬게이트를 제조하는 방법
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
TW200845960A (en) * 2007-04-05 2008-12-01 Wyeth Corp Wortmannin-rapalog conjugate and uses thereof
US20090253733A1 (en) * 2008-04-02 2009-10-08 Biointeractions, Ltd. Rapamycin carbonate esters
WO2009131631A1 (en) * 2008-04-14 2009-10-29 Poniard Pharmaceuticals, Inc. Rapamycin analogs as anti-cancer agents
CN101676291B (zh) * 2008-09-18 2012-05-09 上海海和药物研究开发有限公司 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途
CN104042612A (zh) 2008-11-11 2014-09-17 得克萨斯大学体系董事会 哺乳动物雷帕霉素靶蛋白的抑制
IT1394309B1 (it) 2009-05-22 2012-06-06 Poli Ind Chimica Spa Nuovo approccio chimico-enzimatico alla sintesi del pimecrolimus
WO2015103447A1 (en) 2013-12-31 2015-07-09 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
EP2694520A1 (en) * 2011-04-01 2014-02-12 Sandoz AG Regioselective acylation of rapamycin at the c-42 position
CN104203959B (zh) * 2012-06-08 2017-09-15 百多力股份公司 雷帕霉素40‑o‑环状烃酯、组合物和方法
US10751450B2 (en) 2012-06-08 2020-08-25 Biotronik Ag Rapamycin 40-O-cyclic hydrocarbon esters, compositions and methods
US20160030401A1 (en) 2013-03-13 2016-02-04 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors for prevention of intestinal polyp growth and cancer
CN105102967B (zh) * 2013-03-15 2018-10-12 生物传感器国际集团有限公司 雷帕霉素衍生物的纯化
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
EP3582783B1 (en) 2017-02-17 2023-06-07 Trevena, Inc. 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
EP3624863B1 (en) 2017-05-15 2021-04-14 C.R. Bard, Inc. Medical device with drug-eluting coating and intermediate layer
CA3082831A1 (en) * 2017-11-20 2019-05-23 Icahn School Of Medicine At Mount Sinai Inhibiting trained immunity with a therapeutic nanobiologic composition
US11541152B2 (en) 2018-11-14 2023-01-03 Lutonix, Inc. Medical device with drug-eluting coating on modified device surface
JP7487228B2 (ja) 2019-04-08 2024-05-20 バード・ペリフェラル・バスキュラー・インコーポレーテッド 改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
WO2022128810A1 (en) * 2020-12-14 2022-06-23 Biotronik Ag Materials and methods for treating viral and other medicinal conditions
JP2024511067A (ja) 2021-03-19 2024-03-12 トレインド セラピューティクス ディスカバリー，インコーポレーテッド 訓練された免疫を調節するための化合物およびその使用方法
WO2023070605A1 (en) * 2021-10-29 2023-05-04 Trevena, Inc. Methods of preparing 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds
CN118027062A (zh) * 2023-11-03 2024-05-14 沈阳药科大学 一种雷帕霉素前药及其纳米制剂的制备和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5210030A (en) 1990-06-25 1993-05-11 Merck & Co., Inc. Process for selectively acylating immunomycin
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5233036A (en) 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5260300A (en) 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US6277983B1 (en) 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
TWI256395B (en) 1999-09-29 2006-06-11 Wyeth Corp Regioselective synthesis of rapamycin derivatives
BR0113975A (pt) 2000-09-19 2003-07-29 Wyeth Corp ésteres de rapamicina solúveis em água
RU2344821C2 (ru) 2002-07-30 2009-01-27 Уайт Парентеральные композиции, содержащие гидроксиэфиры рапамицина
BRPI0412667A (pt) 2003-08-07 2006-09-26 Wyeth Corp sìntese regiosseletiva de cci - 779
AU2004270154A1 (en) 2003-09-03 2005-03-17 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
CN1921861A (zh) 2004-01-08 2007-02-28 惠氏公司 用于cci－779的口服给药的可直接压片的药物组合物

Also Published As

Publication number Publication date
EP1737869A1 (en) 2007-01-03
BRPI0509852A (pt) 2007-10-23
WO2005105811A1 (en) 2005-11-10
TW200536542A (en) 2005-11-16
SG152234A1 (en) 2009-05-29
PA8629901A1 (es) 2006-06-02
US20050234234A1 (en) 2005-10-20
UA87492C2 (en) 2009-07-27
ECSP066927A (es) 2006-12-20
GT200500085A (es) 2005-11-03
RU2387657C2 (ru) 2010-04-27
PE20060253A1 (es) 2006-03-30
IL178315A0 (en) 2007-02-11
AU2005238431A1 (en) 2005-11-10
CL2008000507A1 (es) 2008-07-04
CR8646A (es) 2007-08-28
US7268144B2 (en) 2007-09-11
JP2007532134A (ja) 2007-11-15
CN1942476A (zh) 2007-04-04
JP4224115B2 (ja) 2009-02-12
CA2562952A1 (en) 2005-11-10
MXPA06011881A (es) 2006-12-14
AR049019A1 (es) 2006-06-21
KR20070015544A (ko) 2007-02-05
RU2006134014A (ru) 2008-05-20

Similar Documents

Publication Publication Date Title
NO20065090L (no) Regiospesifikk syntese av rapamycin 42-esterderivater
WO2009043803A3 (en) Increasing methionine yield
AR080215A1 (es) Metodo para la produccion de negro de humo con el uso de materia prima precalentada y aparato para su aplicacion
WO2007087827A8 (de) Herstellung von biomassebrennstoff
GB2440083A (en) Apparatus with strake elements and methods for installing strake elements
BRPI0520630A2 (pt) método para unir pelo menos um par de cabos, e, aparelhos para aplicar uma luva tubular elástica sobre uma região de união entre pelo menos um par de cabos e para unir pelo menos um par e cabos
BRPI0815750A2 (pt) processo para recuperar um solvente orgânico e um etanol orgânico de uma mistura de etanol/água.
NO960223L (no) 2,9-disubstituerte purin-6-oner
WO2008045185A3 (en) Process for the preparation of long-chain retinyl esters from short-chain retinyl esters and long-chain acids or long-chain esters employing lipases in organic solvents
GB0817855D0 (en) Artificial bird projectiles for simulating bird strike events
EP1757639A3 (en) Methods for using hollow sphere polymers
BRPI0817826A2 (pt) Formulações herbicidas de éster de fluroxipir meptila com c4-c8 ésteres de triclopir, 2,4-d ou mcpa isentas de solvente aromático.
WO2005121206A3 (en) Polyhydroxyalkanoate having vinyl group, ester group, carboxyl group and sulfonic acid group, and production method thereof
DE502005002595D1 (de) Alkyliden-tetrahydronaphthalinderivate, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer
AR078975A1 (es) Procedimiento para producir derivados de piripiropeno
PL1692256T3 (pl) Fermentor wielkowymiarowy do wytwarzania biogazu z biomasy
WO2008001315A3 (en) Component supplied with an analog value
DE602006013688D1 (de) Neues verfahren zur herstellung von thoc
BR112019010359A2 (pt) processo para a produção de metacrilato de metila
IL181701A0 (en) Improved detoxicant solution
AR065305A1 (es) Metodo de preparacion y separacion estereoselectivas de tri-o-acetil-5-desoxi-beta-d-ribofuranosa
PL1928819T3 (pl) Jednoetapowy sposób wytwarzania estrów diazonaftochinonosulfonylowych
WO2007059421A3 (en) Polymorphs of 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl) amino]-n-methyl-1-benzofuran-3-carboxamide and methods of making the same
AU2003226287A1 (en) Conversion of taxane molecules
Kanda et al. International joint study on the measurement of community response to noise: Comparison of Japanese noise annoyance modifiers between age brackets and areas

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application